

## POSTER ABSTRACTS AT A GLANCE

(POSTERS WILL BE DISPLAYED IN GOVERNOR GENERAL)

POSTER ABSTRACTS	
BOARD	HEALTH SYSTEMS, SERVICES, AND POLICY
1	<p><b>Evaluating an Educational Intervention to Alleviate Distress among Men with Newly-Diagnosed Prostate Cancer and their Partners</b> Presented By: <b>LINDSAY HEDDEN</b>, Postdoctoral Fellow, Centre for Clinical Epidemiology and Evaluation</p>
2	<p><b>Data Insufficiency for Priority Cancer Care Workforce Research in Canada</b> Presented By: <b>LINDSAY HEDDEN</b>, Postdoctoral Fellow, Centre for Clinical Epidemiology and Evaluation</p>
3	<p><b>Operational barriers to the integration of patient reported outcome measures in the Ontario cancer system: A multi-perspective framework</b> Presented By: <b>HEIDI AMERNIC</b>, Research Associate, Cancer Care Ontario</p>
4	<p><b>The Unrecognized Benefits that Communities of Practice can provide to a Provincial Agency</b> Presented By: <b>MICHELLE ANG</b>, Senior Specialist, Cancer Care Ontario</p>
5	<p><b>Predictors of Attrition in Patients With Metastatic Colorectal Cancer (MCRC)</b> Presented By: <b>ARVIN BAHRABDI</b>, University of British Columbia / <b>WINSON CHEUNG</b>, Provincial Director of Health Services Research, Cancer Control Alberta</p>
6	<p><b>Influenza vaccine effectiveness among cancer patients: a population-based study using health administrative and laboratory testing data from Ontario, Canada</b> Presented By: <b>PHILLIP BLANCHETTE</b>, Medical Oncologist, London Regional Cancer Centre</p>
7	<p><b>An environmental scan of knowledge translation activities in cancer surveillance across Canada</b> Presented By: <b>ZEINAB EL-MASRI</b>, Specialist, Knowledge Dissemination &amp; Evaluation, Cancer Care Ontario</p>
8	<p><b>Are screening principles used to inform population-based screening decisions? A scoping review and synthesis of recommendations for colorectal cancer screening</b> Presented By: <b>JESSICA BYTAUTAS</b>, PhD Student, University of Helsinki</p>
9	<p><b>Physicians' Knowledge and Management Practices of Pancreatic Cancer in Nova Scotia: A Mixed Methods Study</b> Presented By: <b>PETER CHO</b>, Medical Student, Dalhousie University</p>
10	<p><b>The Ontario Breast Screening Program Radiologist Outcome Report: Provider Level Performance Monitoring</b> Presented By: <b>LAUREN CHUN</b>, Analyst, Cancer Care Ontario</p>
11	<p><b>Quality of care improvements resulting from a model of care that incorporates the primary clerk into the care team</b> Presented By: <b>JENNIFER COX</b>, Schulich School of Medicine, Western University</p>
12	<p><b>Timeliness of adjuvant chemotherapy in patients with resected pancreatic cancer</b> Presented By: <b>DAVID DENG</b>, Medical Student, University of British Columbia</p>
13	<p><b>Identifying cancer burden and risk factors across geographic areas in Ontario through a new interactive mapping tool</b> Presented By: <b>TODD NORWOOD</b>, Staff Scientist, Cancer Care Ontario</p>
14	<p><b>Cancer System Performance Management: Building a Foundation for Research</b> Presented By: <b>JENNA EVANS</b>, Staff Scientist, Cancer Care Ontario</p>
15	<p><b>Cancer Care Ontario's Communities of Practice: A Scoping Evaluation</b> Presented By: <b>RACHEL GLICKSMAN</b>, Student, Cancer Care Ontario</p>
16	<p><b>Population-Based Standardized Symptom Screening: Cancer Care Ontario's Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Provincial Implementation Approach</b> Presented By: <b>FARZANA MCCALLUM</b>, Lead - Symptom Management, Cancer Care Ontario</p>

17	<b>Benefits of pathway concordance – a survival analysis of colon cancer patients in Ontario</b> Presented By: <b>LUCIANO IERACI</b> , Senior Methodologist, Cancer Care Ontario
18	<b>A Population-Based Retrospective Study Exploring Predictors of Management Strategy in Metastatic Gastric Cancer Patients in Ontario</b> Presented By: <b>YUNNI JEONG</b> , University of Toronto
19	<b>Estimating key parameter in periodic breast cancer screening</b> Presented By: <b>HEDY JIANG</b> , Biostatistician, Cancer Care Ontario
21	<b>Metastatic castration resistant prostate cancer: Changes in prescribing patterns since abiraterone approval in Quebec in 2012</b> Presented By: <b>HALIMA LAHCENE</b> , Student, University of Montreal
22	<b>Continuous Improvement of the Cancer Care Ontario Drug Formulary Website</b> Presented By: <b>NITA LAKHANI</b> , Pharmacist, Cancer Care Ontario
23	<b>Place of death as an Indicator for Cancer Care in Adolescents and Young Adults (AYA) in Canada</b> Presented By: <b>CHARLENE RAE</b> , Research Co-ordinator, McMaster University
24	<b>Epidemiology of Adolescent and Young Adult Cancer in Canada: Incidence, prevalence, survival</b> Presented By: <b>CHARLENE RAE</b> , Research Co-ordinator, McMaster University
25	<b>Investment in Adolescent and Young Adult Cancer Research in Canada</b> Presented By: <b>CHARLENE RAE</b> , Research Co-ordinator, McMaster University
26	<b>Patterns of avoidable vs. unavoidable hospitalizations among cancer patients</b> Presented By: <b>SALLY LAU</b> , Resident, BC Cancer Agency
27	<b>Advancing the Quality of and Access to Health Services in Ontario Using Funding Agreements: CCO's Contract Management Program</b> Presented By: <b>JEN TIN</b> , Coordinator, Contract Management & Diagnostic Assessment Programs, Cancer Care Ontario
28	<b>A population-based study of patient and system factors associated with advanced cutaneous melanoma in Ontario</b> Presented By: <b>MEAGHAN MAVOR</b> , Master's Student, Queen's University
29	<b>Variable Participation of Knowledge Users in Cancer Health Services Research</b> Presented By: <b>MARY ANN O'BRIEN</b> , Assistant Professor, University of Toronto
30	<b>Reliability of Administrative Data for Evaluating Quality of Systemic Cancer Treatment</b> Presented By: <b>MELANIE POWIS</b> , Research Associate, Princess Margaret Cancer Centre - University Health Network
31	<b>Equity in cancer care: An analysis of the Ontario Cancer Plan, and its implications for health equity</b> Presented By: <b>AMBREEN SAYANI</b> , PhD Candidate, York University
32	<b>Socio-demographic correlates of PAP tests for cervical cancer screening in Calgary, Alberta</b> Presented By: <b>SAYEEDA AMBER SAYED</b> , Graduate Student, University of Calgary
33	<b>How does early palliative care affect services used and places of care in the last two weeks of life?</b> Presented By: <b>HSIEN SEOW</b> , Associate Professor / Canada Research Chair in Palliative Care and Health System Innovation, McMaster University
34	<b>Validity testing of the AGREE-HS, a health systems guidance quality appraisal tool</b> Presented By: <b>KAREN SPITHOFF</b> , Research Manager, McMaster University
35	<b>Colonoscopy Quality Management Program 2016 Annual Report – Supporting High-Quality Colonoscopy Care in Ontario</b> Presented By: <b>DAN STRUMPF</b> , Lead, Analytics Quality Management Partnership, Cancer Care Ontario
36	<b>Developing the Breast Utility Instrument - Psychometric (BUI-P): A Multiattribute Health Status Classification System</b> Presented By: <b>TERESA TSUI</b> , PhD student, Toronto Health Economics and Technology Assessment Collaborative
37	<b>Baseline Characteristics as Predictors of Adjuvant Chemotherapy (AC) Toxicities in Stage III Colorectal Cancer (CRC) Patients</b> Presented By: <b>WINSON CHEUNG</b> , Provincial Director of Health Services Research, Cancer Control Alberta

---

38 **An examination of relationships between colonoscopy resource availability and quality and the colorectal cancer diagnostic interval in Ontario, Canada**

Presented By: **COLLEEN WEBBER**, PhD Candidate, Queen's University

---

39 **Radiologist one-year recall recommendation rate after a normal breast screen: Implementing provider practice change by performance monitoring and intervention**

Presented By: **KENNY WONG**, Senior Analyst, Cancer Care Ontario

---

40 **Building consensus: Using modified Delphi methodology to prioritize strategies for improving patient access to chemotherapy-related toxicity management in Ontario**

Presented By: **JANE YAO**, Senior Specialist, Policy, Cancer Care Ontario

---

42 **Colorectal cancer treatment disparities for individuals with a severe psychiatric illness**

Presented By: **ALYSON MAHAR**, Postdoctoral Research Associate, Sunnybrook Research Institute

---

43 **Surgical practice patterns and outcomes of gastric cancer resection for gastric cancer in Ontario: A province-wide study using chart review and health services utilization data**

Presented By: **ALYSON MAHAR**, Postdoctoral Research Associate, Sunnybrook Research Institute

---

44 **Experience Design in Health Care: The Chemotherapy Medication Process from a Pharmacist's Perspective**

Presented By: **JULIE BUELOW**, Communications Advisor, Cancer Care Ontario

---

## BOARD

## HEALTH TECHNOLOGY ASSESSMENT

---

45 **A Database Management Solution for Clinical Cancer Care Research**

Presented By: **AL ARTAMAN**, Epidemiology Director, CancerCare Manitoba

---

46 **Do the American Society of Clinical Oncology (ASCO) Value Framework Version 2 and the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale measure the same construct of clinical benefit?**

Presented By: **SIERRA CHENG**, Research Assistant, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto

---

47 **How Canadian oncology drug prices measure up: A cross-country comparison**

Presented By: **SONYA CRESSMAN**, Health Economist, BC Cancer Agency

---

48 **Have New Drugs for Metastatic or Unresectable Melanoma Improved Survival in the Real World? A Population-Based Study**

Presented By: **TIMOTHY HANNA**, Cancer Care and Epidemiology Division of Queen's Cancer Research Institute

---

49 **The costs of treating metastatic gastric cancer in Ontario: a patient-level exploration of regional variation**

Presented By: **YUNNI JEONG**, University of Toronto

---

50 **Comparative effectiveness of hypofractionated versus conventionally fractionated radiotherapy for low and intermediate risk prostate cancer**

Presented By: **JASON HU**, Student, McGill University

---

51 **The Financial Impact of Cancer Drug Wastage**

Presented By: **CAITLYN LEUNG**, Student, Odette Cancer Centre, Sunnybrook Health Sciences Centre

---

52 **Resource Utilization and Disaggregated Cost Analysis for Initial Treatment of Melanoma**

Presented By: **NICOLE LOOK HONG**, Surgical Oncologist, Sunnybrook Health Sciences Centre

---

53 **Cost-effectiveness of smoking cessation strategies among cancer patients**

Presented By: **LISA MASUCCI**, Health Economist, St. Michael's Hospital

---

54 **Examining the relationship between cost of novel oncology drugs and their value or clinical benefit over time**

Presented By: **RONAK SALUJA**, Research Assistant, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto

---

55 **Using Randomized Pragmatic Studies to Compare Intravenous Access Strategies for Patients Receiving Chemotherapy for breast Cancer 1. not receiving trastuzumab. (REACT-VA Her2 negative) and 2. receiving trastuzumab. (REACT-VA trastuzumab)**

Presented By: **ANDREW ROBINSON**, Medical Oncologist, Kingston General Hospital

---

56	<b>Prolaris and Decipher: Impact on Prostate Cancer Decision of Treatment</b> Presented By: <b>GHADEER OLLEIK</b> , Master's Student in Experimental Surgery, McGill University
57	<b>Are "surrogate" endpoints unbiased metrics compared to hazard ratio for death?: An evaluation of clinical benefit scores (CBS) in the American Society of Clinical Oncology (ASCO) value framework</b> Presented By: <b>MAHIN QURESHI</b> , Research Assistant, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto
58	<b>Shifting trends: An analysis of IV and take-home cancer drug use and public spending in Ontario</b> Presented By: <b>ROHINI NAIPAUL</b> , Senior Pharmacist, Cancer Care Ontario
59	<b>What types of reimbursement recommendations are made for cancer drugs by the pCODR Expert Review Committee using evidence from only nonrandomized trials?</b> Presented By: <b>STEPHANIE ROSS</b> , CADTH
60	<b>Cost-Effectiveness Analysis of the First-Line Use of Biologics for Wild-Type (WT) KRAS Unresectable Metastatic Colorectal Cancer (mCRC) based on primary tumor location</b> Presented By: <b>WILLIAM WL WONG</b> , Assistant Professor, School of Pharmacy, University of Waterloo
61	<b>The impact of pricing strategy on the cost of oral anti-cancer drugs during dose reductions</b> Presented By: <b>JUDY TRUONG</b> , Medical Student, University of Toronto
62	<b>The impact of intravenous cancer drug wastage on economic evaluations</b> Presented By: <b>JUDY TRUONG</b> , Medical Student, University of Toronto
63	<b>Cost-effectiveness of Sunitinib vs. Pazopanib in metastatic renal cell carcinoma (mRCC) patients using real-world data from academic centers in Canada (Ckcis).</b> Presented By: <b>SARA NAZHA</b> , PhD Student, McGill University
64	<b>Cost-utility analysis of the Prolaris test for prostate cancer in patients with a positive biopsy</b> Presented By: <b>ALICE DRAGOMIR</b> , Professor, McGill University
65	<b>Comparative effectiveness and safety of the implementation of universal public funding of FOLFIRINOX (FFX) and gemcitabine (G) + nab-paclitaxel (GnP) in advanced pancreatic cancer (APC): An era-based population-based study in Ontario, Canada</b> Presented By: <b>KELVIN CHAN</b> , Medical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canadian Centre for Applied Research in Cancer Control
66	<b>A real-world population-based comparative symptom analysis of patients with advanced pancreatic cancer (APC) receiving first line FOLFIRINOX (FFX), gemcitabine + nab-paclitaxel (GnP) or gemcitabine (G)</b> Presented By: <b>KELVIN CHAN</b> , Medical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canadian Centre for Applied Research in Cancer Control
67	<b>Cancer Drug Funding Prioritization Frameworks: A systematic review</b> Presented By: <b>PAM TAKHAR</b> , Research Associate, Cancer Care Ontario
68	<b>The cost and cost-trajectory of applying whole-genome analysis to guide treatment for patients with advanced cancers</b> Presented By: <b>DEIRDRE WEYMANN</b> , Health Economist, BC Cancer Agency
69	<b>Radiation Incident Safety Committee: Improving Quality and Safety within Radiation Treatment</b> Presented By: <b>CARINA SIMNICEANU</b> , Specialist, Policy, Cancer Care Ontario
<b>BOARD SURVIVORSHIP</b>	
70	<b>Do Elderly and Young Patients Derive Similar Relative Survival Benefits from Novel Oncology Drugs? A Systematic Review and Meta-Analysis</b> Presented By: <b>VANESSA ARCIERO</b> , Research Assistant, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto
71	<b>Diffuse Large B-cell Lymphoma: A single institution experience of patient outcomes</b> Presented By: <b>RYAN CHAN</b> , Student, University of Toronto
72	<b>Temporal treatments and outcomes following acute myocardial infarction among cancer survivors: a population-based study, 1995-2013</b> Presented By: <b>INNA GONG</b> , MD Candidate, University of Toronto

**BOARD****SOCIETAL VALUES AND PUBLIC ENGAGEMENT**

- 73 **The alignment of patient values with pCODR funding recommendations**  
Presented By: **ZAHRA AKBAR**, Clinical Research Assistant, CADTH-pCODR
- 
- 75 **Health Related Quality of Life in Adult Patients with Cutaneous T-Cell Lymphoma- a Preliminary Analysis**  
Presented By: **SHAZIA HASSAN**, Research Associate, HOPE Research Centre, Sunnybrook Research Institute
- 
- 76 **Developing a KT Strategy for the Canadian Population Attributable Risk (ComPARE) project**  
Presented By: **ROBERT NUTTALL**, Assistant Director, Health Policy, Canadian Cancer Society
- 
- 77 **Maximizing the impact of new information on the burden of cancers caused by the human papillomavirus in Canada**  
Presented By: **LEAH SMITH**, Canadian Cancer Society
- 
- 78 **Exploring the role and identity of informal support for palliative cancer patients in rural and non-rural settings: a literature review**  
Presented By: **LAUREN LOVOLD**, Student, Ryerson University
- 
- 79 **Perceptions around vascular access for intravenous systemic therapy and risk factors for lymphedema in early stage breast cancer – A patient survey**  
Presented By: **SASHA MAZZARELLO**, Clinical Research Coordinator, The Ottawa Hospital Research Institute
- 
- 80 **Optimising vascular access for patients receiving intravenous systemic therapy for early stage breast cancer – A survey of oncology nurses and physicians**  
Presented By: **SASHA MAZZARELLO**, Clinical Research Coordinator, The Ottawa Hospital Research Institute

**BOARD****SURVIVORSHIP**

- 81 **Diffuse large B-cell lymphoma and other lifetime primary malignancy in the Windsor-Essex region**  
Presented By: **JOSHUA KOSTA**, Medical Student, Schulich School of Medicine & Dentistry
- 
- 82 **Development and Evaluation of a Branching Logic Survey for Screening and Evaluating Physical Function in Cancer Survivors**  
Presented By: **MINDY LIAN**, Clinical Research Study Assistant, Princess Margaret Cancer Centre
- 
- 83 **Do Male and Female Patients Derive Similar Survival Benefits from Contemporary Systemic Cancer Therapies? A Systematic Review and Meta-Analysis**  
Presented By: **ERICA MCDONALD**, Cancer Research Assistant, Sunnybrook Health Sciences Centre
- 
- 84 **Development of a Standardized Survivorship Cohort in Ontario**  
Presented By: **STEFANIE DE ROSSI**, Senior Specialist, Survivorship, Cancer Care Ontario
- 
- 85 **The impact of falls in older cancer patients**  
Presented By: **SCHRODER SATTAR**, Doctoral Student, University of Toronto
- 
- 86 **Development Process of a Fertility Decision Aid for Young Canadians Diagnosed with Breast Cancer to Improve Decision-Making**  
Presented By: **BRITTANY SPELLER**, Graduate Student, University of Toronto
- 
- 87 **Isoflavone and lignan intake among breast cancer patients and differences by menopausal status**  
Presented By: **BEATRICE BOUCHER**, Staff Scientist, Cancer Care Ontario
- 
- 88 **Examining the Effect of a Group Psychoeducational Intervention for Cancer-Related Cognitive Dysfunction: A Pilot Study**  
Presented By: **KOMAL SHAIKH**, PhD Candidate, York University